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Background: Cardiovascular disease (CVD) is a leading cause of death in Canada and is a priority area for medical
research. The research funding landscape in Canada has changed quite a bit over the last few decades, as have
funding levels. Our objective was to estimate the magnitude of expenditures on CVD research for the public and
charitable (not-for profit) sectors in Canada between 1975 and 2005.
Methods: To estimate research expenditures for the public and charitable sectors, we compiled a complete list of
granting agencies in Canada, contacted each agency and the Canadian Institutes of Health Research (CIHR), and
extracted data from the organizations’ annual reports and the Reference Lists of health research in Canada. Two
independent reviewers scanned all grant and fellowship/scholarship titles (and summary/key words, when available)
of all research projects funded to determine their inclusion in our analysis; only grants and fellowships/scholarships
that focused on heart and peripheral vascular diseases were selected.
Results: Public/charitable sector funding increased 7.5 times, from close to $13 million (in constant dollars) in 1975
to almost $96 million (in constant dollars) in 2005 (base year). The Medical Research Council of Canada (MRCC)/
CIHR and the Heart & Stroke Foundation of Canada have been the main founders of this type of research during
our analysis period; the Alberta Heritage Foundation for Medical Research and the Fonds de la recherche en santé
du Quebec have played major roles at the provincial level. The Indirect Costs Research Program and Canada
Foundation for Innovation have played major roles in terms of funding in the last years of our analysis.
Conclusion: Public/charitable-funded research expenditures devoted to CVD have increased substantially over the
last three decades. By international standards, the evidence suggests Canada spends less on health-related research
than the UK and the US, at least in absolute terms. However, this may not be too problematic as Canada is likely to
free-ride from research undertaken elsewhere. Understanding these past trends in research funding may provide
decision makers with important information for planning future research efforts. Future work in this area should
include the use of our coding methods to obtain estimates of funded research for other diseases in Canada.
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Cardiovascular diseases (CVD) are responsible for about
one third of all deaths in Canada, and thus pose a con-
siderable burden on society [1]. Not surprisingly, CVD is
a priority focus for health research.
In Canada, public efforts to fund medical research date
back to the first half of the 20th century. In the early
1930s, the National Research Council and the Depart-
ment of Agriculture were the main funding organiza-
tions, providing support for research related to human
illness. In the late 1950s, the Medical Research Council
of Canada (MRCC) was created to address the increas-
ing need for additional research funding. It also served
as an independent body that advised the government on
policy and matters relating to medical research and its
administration. From 1960 to 1990, the MRCC’s funding
from the Government of Canada multiplied almost
one-hundredfold, from $2.3 million to more than $200
million [2]. During that time, the MRCC was the major
grant-funding agency for medical research in Canada [3].
The Canadian Institutes of Health Research (CIHR)
replaced the MRCC in 2000 [4] and had a much broader
mandate than its predecessor, supporting a wide
spectrum of health research, from basic science to clin-
ical research to health services and population health
[5]. It was also endowed with a much larger budget —
by its second year of operation, the annual budget of the
CIHR was close to $500 million, nearly double that of
the MRCC [5]. By 2005, the CIHR provided roughly 12
percent of all health research funding, making it the lar-
gest single funder in Canada [6].
Little has been published on how the magnitude and
source of research expenditures have changed over time.
Understanding past trends in research funding may pro-
vide decision makers with important information for
planning future research efforts. For example, in 2008,
the US National Institutes of Health (NIH) launched a
major effort to code funds by disease area, the Research,
Condition, and Disease Categorization (RCDC) [http://
report.nih.gov/rcdc/] to help obtain accurate estimates
of funded research. Our analysis addresses this gap in
knowledge by estimating the magnitude of past spending
on CVD (heart and peripheral vascular disease) research
from the non-profit (public/charitable) sector in Canada
from 1975 to 2005.
Methods
Broadly speaking, the Canadian health research funding
system can be divided into three groups: public sector
funding (federal and provincial governments), private
sector funding (not-for profit organizations such as
charities and foundations, and for profit organizations –
industry broadly speaking) and international funding
(see Figure 1) [7]; in this analysis, we focus on publicsector funding and private not-for profit sector (char-
ities and foundations) funding only.
Funding organizations in Canada
To obtain data on expenditures of public/charitable-
funded research, we compiled a list of the major national
granting agencies in Canada, such as the Canadian Insti-
tute of Health Research (CIHR), the Natural Sciences
and Engineering Research Council (NSERC) and the So-
cial Sciences and Humanities Research Council
(SSHRC); the major foundations, such as the Heart &
Stroke Foundation of Canada (H&SF of Canada), the
Canada Foundation for Innovation (CFI), Genome
Canada and the Canadian Health Services Research
Foundation (CHSRF); and other major provincial organi-
zations, such as the Fonds de la recherche en santé du
Québec (FRSQ). This list was our stating point.
Next, we undertook an internet search for additional
organizations. This was achieved by searching links on
the websites of organizations already identified (see list
mentioned beforehand) and by general internet searches.
Next, we used a snowball sampling approach when con-
tacting each funder we found, asking if they were aware
of any additional sources of health research funding that
we had not captured in our first search [8]. Finally, we
made use of the Reference Lists of health research in
Canada (which include data on grants and awards col-
lected by the former MRCC and supplied to us by the
CIHR) [9] to provide names of organizations that were
not captured in our search, either because they have
ceased to exist or have changed their name over the
years.
Once a list was compiled, we contacted every
organization to obtain cardiovascular disease research-
related expenditures from 1975 to 2005. Information
was provided either directly by the organization or
through its annual reports; this occurred in 73% of the
cases. When this information was not available or not
provided, we made use of the reference lists. These data
are not openly available; permission to use the data was
obtained from the CIHR or the individual organization.
In most cases, the expenditure data reported in the an-
nual reports were also included in the Reference Lists.
Reference lists of health research in Canada
The Reference Lists of health research contains lists of
the extramural research projects (grants and awards) in
Canada supported by federal, provincial, and voluntary
agencies [9]. The Reference Lists are not a complete rec-
ord for the grants and awards for a given fiscal year [9].
For the majority of the agencies it includes only those
approved prior to July 1 of that year [9]. While some
agencies have completed their awards by that date,
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Figure 1 Funding structure of the Canadian health research system.
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valid reasons prefer not to publicize their awards and no
record can therefore be included [9]. However, in spite
of the fact that the records are incomplete, it reflects the
greater part of awards provided for that year.
The Reference Lists do not include agencies outside of
Canada, such as the US NIH; Canadian and foreign busi-
ness enterprises, including the pharmaceutical industry;
a number of small, mainly local or regional agencies and
foundations; and endowments or other funds at the dis-
cretion of universities, hospitals, and affiliated institu-
tions [9].
In particular, for each research project listed, the fol-
lowing information was available:
1. List number used for identifying the project in the
indices
2. Name of the recipient of the grant/award
3. Department/faculty and the university/institution
where each investigator holds his or her main
academic appointment or is located or where the
research training is being pursued
4. Title of the research project
5. Project number assigned by the granting agency
6. Year in which the project was initiated
7. Classification by department in which the work is
carried out as defined in the Index
8. Funding provided by the agency for the grant or
award in the agency’s latest fiscal period and in the
previous one if applicable.
Coding methodology
Previous research has classified funding by field using
grant abstracts [10,11] and other grant information [12-14], information on the mission of the funding agency or
institute [15] or numbers reported to legislators [16].
The NIH currently uses the Research, Condition, and
Disease Categorization (RCDC) coding, which is based
on coding information from full text of grant applica-
tions. The RCDC method was implemented in 2008 by
the NIH at the request of Congress to provide better
consistency and transparency in the reporting of its
funded research. This method uses sophisticated text
data mining (categorizing and clustering using words
and multiword phrases) in conjunction with NIH-wide
definitions used to match projects to categories, while
improving consistency and eliminating variability in the
definition of the research categories reported.
For our analysis, we classified CVD funding by exam-
ining grant and fellowships/scholarship titles and
abstracts (and summary/key words, when available) as
we did not have access to the full text of the grant. In
particular, two independent reviewers scanned all grant
and fellowship/scholarship titles of all research projects
funded to assess whether these were CVD-related and
eligible for inclusion in our analysis. The grants and fel-
lowships/scholarships were selected if the clinical condi-
tions studied included heart and peripheral vascular
diseases, namely acute myocardial infarction, acute cor-
onary syndrome, acute angina and cardiovascular heart
disease, heart failure, hypertension or hyperlipidemia.
These are the same outcomes examined in the Ontario
IMPACT model [17] and were chosen for the sake of
comparability with previous work on the topic [18]. The
list of grants and fellowships/scholarships of each re-
viewer were then compared to see if they were consist-
ent with one another; when required, the reviewers met
to discuss any inconsistencies regarding a grant/
Table 1 Cardiovascular disease research funding
organizations included in our analysis
Federal Funding
Granting Agencies
• Medical Research Council of Canada (MRCC)/Canadian Institutes of
Health Research (CIHR)
• Canada Council/Social Sciences and Humanities Research Council
(SSHRC)
• Natural Sciences and Engineering Research Council (NSERC)
• Government of Canada, Indirect Costs Research Program
Foundations
• Canada Foundation for Innovation (CFI)




• Prince Edward Island Health Research Institute
• Newfoundland & Labrador Centre for Applied Health Research
Charitable Organizations and Foundations
Charitable Organizations
• Heart & Stroke Foundation of Canada (H&SF in Canada)
• British Columbia Health Care Research Foundation/Michael Smith
Foundation
• Alberta Heritage Foundation for Medical Research (Alberta Innovates -
Health Solutions since 2010)
• Saskatchewan Health Research Board/ Health Services Utilization and
Research Commission/ Saskatchewan Health Research Foundation
• Conseil de la recherche en santé du Québec (CRSQ)/Fonds de la
recherche en santé du Québec (FRSQ)
Foundations
• Manitoba Medical Service Foundation
• Manitoba Health Research Council
• Banting Research Foundation
• J.P. Bickell Foundation
• Nova Scotia Health Research Foundation
• Dalhousie Medical Research Foundation
• The Physicians' Services Incorporated Foundation
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sus. This selection method was applied to all organiza-
tions and years of our analysis.
Fortunately, we did not have many cases of missing
data; we employed linear interpolations in two cases only
(one data point for the H&SF of Canadaa and the FRSQ,b
respectively) to obtain missing expenditure estimates.
Furthermore, we generally made less assumptions com-
pared to previous work on the same topic [18]. For ex-
ample, we did not assume all expenditure data from the
H&SF of Canada were relevant to our analysis; we
reviewed each individual grant title to assess its inclusion
in our analysis.
We estimated the value of expenditures in constant
dollars, adjusted by the Consumer Price Index to 2005
dollars [19]. “Constant dollars” refers to the monetary
value of prior expenditures expressed in currency units
for a fixed, base year (in our case, 2005), after adjusting
for the effect of inflation.
Results
Table 1 lists the public/charitable organizations found in
our search; all organizations, except the Newfoundland
& Labrador Centre for Applied Health Research, pro-
vided funding for cardiovascular-related research during
our analysis period. Figure 2 provides an overview of the
trend for cardiovascular-related research for non-profit
funding sources in Canada from 1975 to 2005. In 1975,
these expenditures were $13 million while in 2005 this
value had increased to $96 million (in constant dollars).
There is the possibility that we did not capture all orga-
nizations that funded CVD research during our analysis
period; however, given that most federal, provincial, and
voluntary agencies reported to the MRCC [9], we feel
that this is not too problematic.
Some organizations have contributed quite a bit to the
overall amount of cardiovascular research-related expen-
ditures while others have contributed very little or not at
all. For example, in 1975, the H&SF of Canada was the lar-
gest funder of CVD research, funding close to 62% of all
grants and scholarships/fellowships; the MRCC funded
roughly 35% of those research endeavours. These two
organizations alone covered the vast majority of CVD-
related research initiatives – close to 97% (see Figure 3).
At the provincial level, the Conseil de la recherché en
santé du Quebec (CRSQ) stood out as one of the top fun-
ders (3.2%).
Ten years later, in 1995, the funding landscape in
Canada had changed quite a bit – while the H&SF of
Canada and the MRCC continued to be the main funders,
the proportion of how much they funded had changed a
bit. While the MRCC’s importance increased slightly, now
funding 38%, the H&SF of Canada proportion of funding
had fallen to 41%. Funders at the provincial level werestarting to have a larger role in funding, with the Alberta
Heritage Foundation for Medical Research (AHFMR) pro-
viding funding for close to 16% of all CVD-related grants
and the Fonds de la recherche en santé du Quebec (FRSQ)
(former CRSQ) funding close to 6%.
In 2005, the CIHR (former MRCC) was the largest
funder (42%), followed by the H&SF of Canada (28%), the
newly created Indirect Costs Research Program (ICRP)
(11%) and the CFI (7%). To undertake research-related
activities, institutions need to invest in research infra-
structure, such as state-of-the-art equipment, buildings,
laboratories, and databases required to conduct research.




























































































Figure 2 Expenditures on cardiovascular R&D for public/charitable organizations in Canada, 1975–2005.
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infrastructure. It usually funds up to 40% of a project’s in-
frastructure costs. The ICRP was created in 2003; through
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Figure 3 Expenditures on cardiovascular R&D for the top public/charresearch projects each year via its three granting agencies
(CIHR, NSERC and SSHRC). The creation of these last
two organizations explains, in part, the sharp increase
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the FRSQ were still major funders, though their import-
ance has decreased a bit (3% and 4%, respectively).
Discussion
Canadian funding for health research has varied over the
last few decades. Our work focused specifically on the
magnitude of public/charitable funding on cardiovascular
disease (CVD)-related research from 1975 to 2005. These
sectors’ spending have increased over this 20-year
period but mostly in the last decade. In particular,
public/charitable sectors expenditures first rose after 1998,
from $39 million to $48 million, and then again from
2000 onwards, from $72 million to just over $90 million.
A closer look at the composition of the public/charitable
sectors expenditure trends over time show that the H&SF
of Canada and the MRCC have been the main funders
and drivers of CVD research in Canada during our ana-
lysis period (Figure 3). From 1975 to the mid-80s, the
H&SF of Canada and the MRCC funded the majority of
CVD-related research. After that, provincial agencies, such
as the AHFMR and the FRSQ, started to gain importance.
The ICRP and CFI became major funders in the later years
of our analysis, after their creation.
This first major increase in CVD funding can be
attributed to several factors. In 2000, the MRCC transi-
tioned to the CIHR with a broader mandate and
endowed with a larger budget [5]. In addition, after 1999
the H&SF of Canada started funding research chairs in
cardiovascular and stroke research, providing additional
funding for researchers [9]. Finally, the creation of both
the CFI and the CHSRF in 1997 contributed to an in-
crease in overall funding. The second major increase in
funding can be explained, in part, by the creation of sev-
eral other organizations. Genome Canada was estab-
lished in 2000 to develop and implement a national
strategy to support large-scale genomics and proteomics
research. The ICRP followed in 2003.
Over our analysis period, public/charitable sectors
expenditures increased by a factor of almost 7.5. However,
compared to the UK, Canada has spent far less on total
public/charitable cardiovascular-related research over the
last 30 years. In particular for the public/charitable sec-
tors, Canada spent almost $13 million on cardiovascular-
related research in 1975 for a population of about 23
million – roughly $0.60 per person. The UK spent about
$4.50 per person, 8 times the Canadian value for a popula-
tion twice as large [18]. In 1992, seventeen years later,
Canada spent about $1.42 per person on cardiovascular-
related research, while the equivalent UK value was $4.23.
The UK has traditionally spent more on research-related
activities than Canada [18], which largely explains this dif-
ference. Furthermore, this result may be due to different
approaches in estimating expenditure data. Nonetheless,the gap in research expenditures between the two coun-
tries has decreased in the last years, attributed largely
to creation of the CIHR and other research-funding
organizations.
Other research reports that overall biomedical and health
services research spending per capita in Canada in 1985
($17) was slightly more than half that of the US ($30) [20].
More recent data also show that Canada spends substan-
tially less on CVD-related research than the US. Data from
the NIH (using the RCDC method) shows that for 2008
about $4.6 billion dollars (USD) were spent on CVD-
related research (this includes atherosclerosis, cardiovascu-
lar, heart disease, heart disease – coronary heart disease,
hypertension and stroke) [21]. (Unfortunately, we do not
have the figures for 2005; however, it is likely that this value
has not changed much.)
By international standards, the evidence suggests
Canada spends less on health-related research than the
UK and the US, at least in terms of absolute values;
however, to fully gauge the impact of Canada’s research
investment would require understanding how CVD re-
search expenditures lead to changes in health. From
1994 to 2004, we witnessed a drop in the adult CVD-
attributable death rate of about 30% [22]. The extent to
which this is attributable to new research is unclear and
beyond the scope of this analysis; these health gains are
likely a result of not only research undertaken in Canada
but also research undertaken elsewhere. However, new
discoveries have undoubtedly played some role. An im-
portant area for further research is to quantify the rela-
tionship between expenditures and health gains, through
a formal return on investment analysis [23]. Other juris-
dictions, such as the UK, have undertaken such analyses
and found that for every $1 spent on public/charitable
CVD-related research, UK citizens would receive an in-
come stream of about £0.09 per year in perpetuity.
While this type of analysis would allow us to ascertain
whether Canada is spending too much or not on re-
search, this too is beyond the scope of this paper.
These estimates provide policy makers and the CEOs
of granting agencies a depiction of funding trends in
CVD research from not-for profit organizations; that is,
it sheds some light on how public/charitable money has
been spent on CVD-related research and where the funds
have come from. There is an ongoing debate among pol-
icy makers regarding the government’s role in producing
scientific and technical knowledge. One of the main
issues concerns how much public money should be spent
on scientific research and which areas of research should
receive funding [13]. These figures can serve as im-
portant inputs in planning future research budgets and
setting priorities for resource allocation in CVD re-
search. Factors such as public health needs, scientific
opportunities, the quality of research proposals, and
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to be taken into account when deciding how to allo-
cate funds [24]. Efforts to plan disease-oriented re-
search activities are also influenced by projections of
future patterns of disease and the effects of demo-
graphic changes (such as aging) and personal habits
(such as tobacco use) [24].
Several limitations of our analysis merit discussion.
We attempted to estimate all cardiovascular research-
related expenditures for public/charitable sectors. Al-
though we may not have accounted for all expenditures,
we captured most of them. More importantly, for most
organizations we were able to account for all cardiovas-
cular research-related activities, which enhanced the pre-
cision of our analysis. Our analysis also required making
some assumptions in a few instances (such as linear
interpolation) to reach our final estimates.
Notwithstanding these concerns, we believe that we
have reached plausible estimates that not only improve
our understanding of this topic but also provide substan-
tial improvements over previous work. Buxton et al.’s
time series of estimated public/charitable UK expendi-
tures on medical research in cardiovascular disease was
pieced together from a variety of sources and incorpo-
rated multiple assumptions and interpolations [18]. We
believe that our estimates are more reliable for several
reasons. First, we included a review of all grants, awards,
fellowships and scholarships. Second, since the majority
of our data were from the same source,c we can assume
that the data used in our analysis have been reported
consistently over time. Third, we employed few linear
interpolations in our analysis. Finally, we also made
fewer assumptions [18]. Thus, this study’s contributions
to the field are two-fold: a detailed description of the
health care funding landscape for not-for profit organi-
zations in Canada and a consistent time series of public
and charitable sectors expenditure estimates for Canad-
ian CVD-related medical research from 1975 to 2005.
Conclusion
Public/charitable-funded research expenditures devoted
to CVD have increased substantially over the last three
decades. By international standards, the evidence sug-
gests Canada spends less on health-related research than
the UK and the US, at least in absolute terms. However,
this may not be too problematic as Canada is likely to
free-ride from research undertaken elsewhere. Under-
standing these past trends in research funding may pro-
vide decision makers with important information for
planning future research efforts.
Future work in this area should include the use of
these methods and others (such as the RCDC method)
to obtain estimates of funded research for other diseases.
For example, the NIH provides biennially estimates ofthe annual support level for various research, condition,
and disease categories based on grants, contracts, and
other funding mechanisms. It would be interesting to
undertake the same exercise for research funded by the
CIHR or for all major Canadian funding agencies. These
numbers would then enable one to assess whether too
little/much was being spent on research for a particular
disease given its burden [16]. Furthermore, it may be
worthwhile developing a comprehensive approach to de-
termining the health-related and broader social benefits
associated with investments in medical research.
Endnotes
a Only one value (the fiscal year of 1999/00) was inter-
polated using a linear function as the data were not
available (there was no external report available).
b Only one value (the fiscal year of 1983/84) was inter-
polated using a linear function as the grant titles were
not available.
c Data were obtained from either the Reference Lists or
from the actual organization (annual reports); expenditure
trends for some organizations were from both sources.
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